Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 3, 2000, Pages 783-786

  Stoddart, Cheryl A ^a,d   Moreno, Mary E ^a   Linquist Stepps, Valerie D ^a   Bare, Christopher ^a   Bogan, Mark R ^a   Gobbi, Alberto ^a,e   Buckheit Jr , Robert W ^b   Bedard, Jean ^c   Rando, Robert F ^c   McCune, Joseph M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c Shire Canada   (Canada)

^d GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 3' OXATHIOCYTIDINE; CYTIDINE DERIVATIVE; LAMIVUDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION; TISSUE CULTURE; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MICE; MICE, SCID; REVERSE TRANSCRIPTASE INHIBITORS; THIONUCLEOSIDES; VIRUS REPLICATION;

EID: 0033998526     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.3.783-786.2000     Document Type: Article

References (32)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Aldrovandi, G. M., G. Feuer, L. Gao, B. Jamieson, M. Kristeva, I. S. Y. Chen, and J. A. Zack. 1993. The SCID-hu mouse as a model for HIV-1 infection. Nature 363:732-736.
3. Aldrovandi, G. M., L. Gao, G. Bristol, and J. A. Zack. 1998. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J. Virol. 72:7032-7039.
4. Arts, E. J., M. E. Quiñones-Mateu, J. L. Albright, J.-P. Marois, C. Hough, Z. Gu, and M. A. Wainberg. 1998. 3′-Azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. J. Virol. 72:4858-4865.
5. Bedard, J., D. L. Taylor, L. A. Kelly, L. A. Wood, A. S. Tyms, J. M. McCune, C. A. Stoddart, and R. F. Rando. 1999. Anti-HIV activity, drug combination, and resistance studies of dOTC (BCH-10652). Antivir. Res. 41:A19. (Abstract 44.)
6. Berkowitz, R. D., S. Alexander, C. Bare, V. Linquist-Stepps, M. Bogan, M. E. Moreno, L. Gibson, E. D. Wieder, J. Kosek, C. A. Stoddart, and J. M. McCune. 1998. CCR5- and CXCR4-utilizing strains of human immunodeficiency virus type 1 exhibit differential tropism and pathogenesis in vivo. J. Virol. 72:10108-10117.
7. Bonyhadi, M. L., L. Rabin, S. Salimi, D. A. Brown, J. Kosek, J. M. McCune, and H. Kaneshima. 1993. HIV induces thymus depiction in vivo. Nature 363:728-732.
8. Boucher, C. A., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
9. Carpenter, C. C. J., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1998. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 280:78-86.
10. Datema, R., L. Rabin, M. Hincenbergs, M. B. Moreno, S. Warren, V. Linquist, B. Rosenwirth, J. Seifert, and J. M. McCune. 1996. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob. Agents Chemother. 40:750-754.
11. de Muys, J.-M., H. Gourdeau, N. Nguyen-Ba, D. L. Taylor, P. S. Ahmed, T. Mansour, C. Locas, N. Richard, M. A. Wainberg, and R. F. Rando. 1999. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob. Agents Chemother. 43:1835-1844.
12. Kaneshima, H., L. Su, M. L. Bonyhadi, R. I. Connor, D. D. Ho, and J. M. McCune. 1994. Rapid-high, syncytium-inducing isolates of human immunodeficiency virus type 1 induce cytopathicity in the human thymus of the SCID-hu mouse. J. Virol. 68:8188-8192.
13. Kavlick, M. F., T. Shirasaka, E. Kojima, J. M. Pluda, F. Hui, Jr., R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir. Res. 28:133-146.
14. Kitchen, S. G., and J. A. Zack. 1997. CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J. Virol. 71:6928-6934.
15. Mansour, T. S., H. Jin, W. Wang, D. M. Dixit, C. A. Evans, H. L. A. Tse, B. Belleau, J. W. Gillard, E. Hooker, C. Ashman, N. Cammack, H. Salomon, A. R. Belmonte, and M. A. Wainberg. 1995. Structure-activity relationships among a new class of antiviral heterosubstituted 2′,3′-dideoxynucleoside analogues. Nucleosides Nucleotides 14:627-635.
16. Mansour, T. S., H. Jin, W. Wang, E. U. Hooker, C. Ashman, N. Cammack, H. Salomon, A. R. Belmonte, and M. A. Wainberg. 1995. Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J. Med. Chem. 38:1-4.
17. McCune, J. M. 1997. Animal models of HIV-1 disease. Science 278:2141-2142.
18. McCune, J. M., R. Namikawa, H. Kaneshima, L. D. Shultz, M. Lieberman, and I. L. Weissman. 1988. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639.
19. Miller, M. D., K. E. Anton, A. S. Mulato, P. D. Lamy, and J. M. Cherrington. 1999. Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro. J. Infect. Dis. 179:92-100.
20. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55-63.
21. Namikawa, R., H. Kaneshima, M. Lieberman, I. L. Weissman, and J. M. McCune. 1988. Infection of the SCID-hu mouse by HIV-1. Science 242: 1684-1686.
22. Namikawa, R., K. N. Weilbaecher, H. Kaneshima, E. J. Yee, and J. M. McCune. 1990. Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 172:1055-1063.
23. Rabin, L., M. Hincenbergs, M. B. Moreno, S. Warren, V. Linquist, R. Datema, B. Charpiot, J. Seifert, H. Kaneshima, and J. M. McCune. 1996. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Antimicrob. Agents Chemother. 40:755-762.
24. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
25. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
26. Stanley, S. K., J. M. McCune, H. Kaneshima, J. S. Justement, M. Sullivan, E. Boone, M. Baseler, J. Adelsberger, M. Bonyhadi, J. Orenstein, C. H. Fox, and A. S. Fauci. 1993. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J. Exp. Med. 178:1151-1163.
27. Stoddart, C. A. 1999. The SCID-hu Thy/Liv mouse: an animal model for HIV-1 infection, p. 1069-1076. In O. Zak and M. A. Sande (ed.), Handbook of animal models of infection. Academic Press, London, United Kingdom.
28. Stoddart, C. A., L. Rabin, M. Hincenbergs, M. E. Moreno, V. Linquist-Stepps, J. M. Leeds, L. A. Truong, J. R. Wyatt, D. J. Ecker, and J. M. McCune. 1998. Inhibition of human immunodeficiency virus type 1 infection in SCID-hu Thy/Liv mice by the G-quartet-forming oligonucleotide, ISIS 5320. Antimicrob. Agents Chemother. 42:2113-2115.
29. Su, L., H. Kaneshima, M. L. Bonyhadi, R. Lee, J. Auten, A. Wolf, B. Du, L. Rabin, B. H. Hahn, E. Terwilliger, and J. M. McCune. 1997. Identification of HIV-1 determinants for replication in vivo. Virology 227:45-52.
30. Su, L., H. Kaneshima, M. Bonyhadi, S. Salimi, D. Kraft, L. Rabin, and J. M. McCune. 1995. HIV-1-induced thymocyte depletion is associated with indirect cytopathicity and infection of progenitor cells in vivo. Immunity 2:25-36.
31. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
32. Wainberg, M. A., H. Salomon, Z. Gu, J. S. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.